Natalay Kouprina received her M.Sc. in physical chemistry from the St. Petersburg State University, Russia, and her Ph.D. and Dr.Sc. in cell biology from the Institute of Cytology, Russian Academy of Sciences. While in Russia, she worked on the identification of genes that control the replication and segregation of chromosomes in budding yeast. In 1991, she moved to the United States and focused her interests on genomics. At present, she is a staff scientist/leader of the group at the National Cancer Institute, USA. Presently, Dr. Kouprina serves as Editorial Board Member of several referred journals and invited as a consultant to Nature Communications. She also was an Invited Guest Editor of special issues of few high-rank journals. Natalay Kouprina was an organizer and a co-organizer of several international conferences.
Her current interest is to combine a transformation-associated recombination (TAR) cloning technology that allows selective isolation of a gene of interest up to 300 kb in size from complex genomes, including humans, with the human artificial chromosome or HAC-based gene delivery vector to develop a novel system for the delivery and expression of full-length mammalian genes. Such a novel approach has a potential for gene functional studies, gene therapy and biomedicine. She has 107 publications in many leading journals, including chapters in the books. Also, she is the inventor of several US patents, some exclusively licensed by a private sector. She has several Merit awards from NIH for superior competence and outstanding productivity in research endeavors.
Dr.Huang was born in Fuzhou, China. He received his PhD degree in Nuclear Science and Engineering (Radioanalytical Chemistry) from MIT, earned a Master’s Degree in chemistry from Tufts University, and a bachelor’s degree in radiation chemistry from University of Science & Technology of China. He is the Co-Director of Neurochemistry Lab, Department of Psychiatry, Massachusetts General Hospital (MGH), a teaching affiliate of Harvard Medical School (HMS); a faculty member of HMS.
His research thrust is to high-throughput screen and design, synthesize, and characterize targeted theranostic compounds for human diseases such as Alzheimer’s disease, cancer, and cardiovascular diseases, etc. In addition, his lab is exploring novel applications of biomedical informatics (such as medical image analysis and bioinformatics) and cheminformatics (such as structure-based rational drug design and in-silico drug screening) in systems biology and nanotechnology in translational medicine.